SCHEMBL30730612

SCHEMBL30730612

Cc1nonc1CC(=O)N1CCC(n2cnc(-c3ccc(F)cc3)n2)CC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
MAPK1 P28482 2/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
PKM P14618 2/20 0.43
ALDH1A1 P00352 2/20 0.42
CNR1 P21554 1/20 0.40
GFER P55789 1/20 0.40
GRM5 P41594 1/20 0.39
KCNH2 Q12809 1/20 0.39
MC4R P32245 1/20 0.39
KMT2A Q03164 3/20 0.38
MEN1 O00255 1/20 0.38
RAB9A P51151 1/20 0.38
CCR3 P51677 1/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPK14 Q16539 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730703 0.83 LMNA (0.41) LMNAMAPK1ALOX15TSHRPKM
SCHEMBL30730585 0.83 LMNA (0.47) LMNAMAPK1ALOX15TSHRPKM
SCHEMBL30730484 0.81 LMNA (0.49) LMNAMAPK1ALOX15TSHRPKM
SCHEMBL30730491 0.81 KDM5C (0.44) LMNAMAPK1ALOX15TSHRPKM
SCHEMBL30730662 0.80 LMNA (0.71) LMNAMAPK1ALOX15TSHRALDH1A1
SCHEMBL30730435 0.79 LMNA (0.43) LMNAMAPK1ALOX15TSHRPKM
SCHEMBL30730486 0.77 KMT2A (0.45) LMNAMAPK1ALOX15TSHRPKM
SCHEMBL30730427 0.75 LMNA (0.54) LMNAMAPK1ALOX15TSHRPKM
SCHEMBL30730513 0.74 LMNA (0.48) LMNAMAPK1ALOX15TSHRPKM
SCHEMBL30730690 0.74 LMNA (0.46) LMNAMAPK1ALOX15TSHRPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 LMNA 1838/4885MAPK1 1861/4885ALOX15 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.